Astellas To Pay $3bn For Gene Therapy Company Audentes
Acquisition Includes Lead Asset AT132
Japanese company joins the ranks of big pharma buying up gene therapy pioneers
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
The recent reimbursement and launch of Zolgensma showed Japan willing and able to approve and pay for gene therapies, and others including from Otsuka/Takara Bio are moving forward under a supportive regulatory framework.
Financing for biopharma companies increased by 19% in Q4 to $15.8bn. M&A value quadrupled, compared with Q3, thanks to nine billion-dollar-plus transactions, led by the buy-out of Nestle Skin Health, now Galderma.Among the key alliances of Q4 were recurring themes of gene therapy and oncology, but also big investments in oligonucleotide technologies.